{'fraction_non_alphanumeric': 0.03343023255813953, 'fraction_numerical': 0.027616279069767442, 'mean_word_length': 5.5, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Remdesivir in Hospitalized Adults With Severe COVID-19: Lessons Learned From the First Randomized Trial

Y Wang et al conducted a study to examine the efficacy, safety, and clinical benefit of remdesivir in hospitalized adults with confirmed pneumonia due to severe SARS-CoV-2 infection The randomized, investigator-initiated, placebo-controlled, double-blind, multicenter trial took place between February 6, 2020 and March 12, 2020, at 10 hospitals in Wuhan China This study found that, compared with placebo, intravenous remdesivir did not significantly improve the time to clinical improvement, mortality, or time to clearance of SARS-CoV-2 in hospitalized adults with severe COVID-19